ZYME Quote, Financials, Valuation and Earnings

Jazz Pharmaceuticals Plc has a net margin of -70.99% compared to Zymeworks, Inc.'s net margin of 22.33%. Zymeworks, Inc.'s return on equity of -18.82% beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.

Zymeworks, Inc. has a consensus price target of $35.54, signalling upside risk potential of 53.85%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $214.06 which suggests that it could grow by 33.58%. Given that Zymeworks, Inc. has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe Zymeworks, Inc. is more attractive than Jazz Pharmaceuticals Plc.

Zymeworks, Inc. has a beta of 1.300, which suggesting that the stock is 30.008% more volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.272, suggesting its less volatile than the S&P 500 by 72.796%.

Zymeworks, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks, Inc. pays -- of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend.

Zymeworks, Inc. quarterly revenues are $27.6M, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. Zymeworks, Inc.'s net income of -$19.6M is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, Zymeworks, Inc.'s price-to-earnings ratio is -- while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks, Inc. is 13.01x versus 2.35x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -70.99% compared to Zymeworks, Inc.'s net margin of 21.47%. Zymeworks, Inc.'s return on equity of -18.82% beat Johnson & Johnson's return on equity of 33.27%.

Zymeworks, Inc. has a consensus price target of $35.54, signalling upside risk potential of 53.85%. On the other hand Johnson & Johnson has an analysts' consensus of $211.38 which suggests that it could grow by 2.74%. Given that Zymeworks, Inc. has higher upside potential than Johnson & Johnson, analysts believe Zymeworks, Inc. is more attractive than Johnson & Johnson.

Zymeworks, Inc. has a beta of 1.300, which suggesting that the stock is 30.008% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.

Zymeworks, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.5% to investors and pays a quarterly dividend of $1.30 per share. Zymeworks, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zymeworks, Inc. quarterly revenues are $27.6M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Zymeworks, Inc.'s net income of -$19.6M is lower than Johnson & Johnson's net income of $5.2B. Notably, Zymeworks, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 19.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks, Inc. is 13.01x versus 5.41x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -70.99% compared to Zymeworks, Inc.'s net margin of 38.89%. Zymeworks, Inc.'s return on equity of -18.82% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Zymeworks, Inc. has a consensus price target of $35.54, signalling upside risk potential of 53.85%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $821.12 which suggests that it could grow by 2.51%. Given that Zymeworks, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Zymeworks, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Zymeworks, Inc. has a beta of 1.300, which suggesting that the stock is 30.008% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Zymeworks, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.44% to investors and pays a quarterly dividend of $0.88 per share. Zymeworks, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Zymeworks, Inc. quarterly revenues are $27.6M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Zymeworks, Inc.'s net income of -$19.6M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Zymeworks, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 19.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks, Inc. is 13.01x versus 6.20x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -70.99% compared to Zymeworks, Inc.'s net margin of 34.76%. Zymeworks, Inc.'s return on equity of -18.82% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Zymeworks, Inc. has a consensus price target of $35.54, signalling upside risk potential of 53.85%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $496.16 which suggests that it could grow by 5.64%. Given that Zymeworks, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Zymeworks, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Zymeworks, Inc. has a beta of 1.300, which suggesting that the stock is 30.008% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.310, suggesting its less volatile than the S&P 500 by 69.005%.

Zymeworks, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Zymeworks, Inc. quarterly revenues are $27.6M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Zymeworks, Inc.'s net income of -$19.6M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Zymeworks, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 33.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks, Inc. is 13.01x versus 10.37x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.